STAT Stitch Deep Dive Podcast Beyond The Bedside

STAT Stitch Deep Dive Podcast Beyond The Bedside

by Regular Guy

Courses Life Sciences

Season 7

CC Pharm | Fentanyl

Fentanyl (Sublimaze): Elite Nursing 80/20 Summary 1. ID & Action: Phenylpiperidine synthetic opioid agonist. Binds mu/kappa receptors. Inhibits adenylyl cyclase, decreasing cAMP to block release of neurotransmitters (substance P, GABA, dopamine, acetylcholine, norepinephrine). Highly lipophilic (580:1 vs. morphine); rapid onset. 2. Therapeutic Use: General/spinal anesthesia adjunct; chronic and breakthrough pain (transmucosal/nasal only). 3. 80/20 Formulations (NOT Interchangeable mcg-to-mcg): IV/IM: Peak IV analgesia in minutes. Inject slowly over 1–3 min; rapid injection can cause apnea or chest wall rigidity. Transdermal Patch: Onset 12–24h; changed every 72h. Epidermal depot slowly absorbs. Critical: Avoid external heat (pads, saunas, fevers >104°F); heat increases absorption by 120%, risking fatal overdose. Clip, do not shave, hair. Fold adhesive inward and flush. Transmucosal (Actiq, Fentora, Onsolis, Abstral, Subsys, Lazanda): For breakthrough pain in opioid-tolerant patients ONLY. Follow specific directions (e.g., suck Actiq lozenge, do not chew; do not suck/chew/swallow Abstral). Dry hands. Flush unneeded forms or use specific pouches. Ionsys: Iontophoretic system (hospital only). Delivers dose via 10-min current. Wear gloves; never touch hydrogels. 4. High-Yield Contraindications & Precautions: Respiratory: Contraindicated in severe respiratory depression or acute/severe asthma in unmonitored settings. Renal/Hepatic: Reduce transdermal dose by 50% in mild-to-moderate impairment; avoid in severe. Pregnancy: Prolonged maternal use causes Neonatal Opioid Withdrawal Syndrome (NOWS); monitor newborn for tremors, high-pitched cry, irritability, vomiting, and diarrhea. 5. Black Box Warnings & Toxicity: Addiction, abuse, misuse, and fatal respiratory depression. Accidental Exposure: Ingestion of patches is fatal, especially in children. Wash hands after handling. Reversal: Keep Naloxone (Narcan) and resuscitative equipment readily available. 6. Key Drug Interactions: CYP3A4 Inhibitors: Prevent fentanyl metabolism, increasing levels and risk of fatal respiratory depression. CNS Depressants: Cause profound sedation, respiratory depression, coma, and death. 7. Nursing Interventions: Assess: Prioritize respiratory rate, depth, and pupil size (miosis). Monitor pain and sedation. Monitor: Use continuous pulse oximetry for infusions. Monitor patch adhesion, especially in pediatric or cognitively impaired patients. Hold & Notify: If RR < 12/min, shallow breathing, or excessive sedation.

CC Pharm | Precedex

Pharmacological Action & Use: Dexmedetomidine (Precedex) is a selective, centrally-acting alpha-2 adrenergic receptor agonist. Presynaptic activation inhibits norepinephrine release and pain signals; postsynaptic CNS activation inhibits sympathetic activity, decreasing heart rate and blood pressure. This produces arousable sedation, anxiolysis, and mild analgesia without significant effects on respiratory drive. It is indicated for ICU ventilator sedation, procedural sedation, and acute psychiatric agitation (sublingual film). Why Choose It: Unlike benzodiazepines or propofol, it sedates without causing respiratory depression, making it ideal for weaning mechanically ventilated patients. It is 8 times more selective for alpha-2 receptors than clonidine. Complications & Safety Concerns: The most common adverse reactions are dose-related bradycardia and hypotension. Rapid IV administration can activate peripheral alpha-2 receptors, causing transient hypertension and reflex bradycardia. Other severe risks include ARDS, atrial fibrillation, and cardiac arrest. Critical Administration Rules: Intravenous: Standard ICU dilution is 4 mcg/mL. Never give via IV push. Infuse loading doses over 10 minutes; however, loading doses are frequently bypassed in practice to avoid severe bradycardia and hypotension. Run on a controlled device. Do not coadminister in the same catheter with blood, serum, or plasma. Sublingual Film (Igalmi): Dissolves in 6–8 minutes. Administer only under direct medical supervision. Instruct the patient not to chew/swallow the film, and avoid food or drink for 15 minutes after sublingual (or 1 hour after buccal) administration. Peak reductions in HR and BP occur 2 hours post-dose; patients must remain seated/lying down and be assessed for orthostatic hypotension before ambulating. When to Hold Sublingual Film: SBP < 90 mmHg, DBP < 60 mmHg, HR < 60 bpm, or a postural drop of SBP ≥ 20 mmHg / DBP ≥ 10 mmHg. Hepatic Impairment: Requires initial IV dose reductions and strict sublingual dose limits (e.g., 60–120 mcg initial dose based on Child-Pugh severity) due to liver metabolism. Clinical Mnemonic & Scenario: Mnemonic: PREcedex = Prevents Respiratory Embarrassment (spares the respiratory drive). Scenario: A ventilated ICU patient is undergoing a spontaneous breathing trial but becomes highly agitated. Precedex is initiated because it calms the patient and maintains arousability without suppressing their respiratory drive. THE 20% TO REMEMBER: Arousable sedation with zero respiratory depression. Bypass IV loading doses to prevent severe bradycardia and hypotension. Assess vitals 2 hours after sublingual dose; hold if HR < 60 or BP < 90/60. No food/water for 15 mins (sublingual) / 1 hour (buccal).

CC Pharm | Milrinone

Core Profile & Mechanism Milrinone is a parenteral positive inotrope and vasodilator with selective phosphodiesterase III (PDE3) inhibitor activity. By preventing cyclic adenosine monophosphate (cAMP) breakdown in cardiac and vascular muscle cells, it increases myocardial contractility, causes vasodilation, and improves diastolic relaxation (lusitropy). This dual action reduces preload, afterload, and systemic vascular resistance with little to no chronotropic activity. Therapeutic effects occur at plasma levels of 100 to 300 ng/mL. Primary Indications Milrinone is used for the short-term treatment of acute heart failure and other low cardiac output states like cardiogenic shock or post-cardiac surgery low cardiac output syndrome (LCOS). It can provide long-term palliative support in stage D heart failure patients awaiting transplant or mechanical circulatory support. Off-label uses include pediatric septic shock or postresuscitation stabilization, cerebral vasospasm after aneurysmal subarachnoid hemorrhage, and persistent pulmonary hypertension of the newborn (PPHN) with poor nitric oxide response. Dosing & Administration Adult HF Dosing: A 50 mcg/kg IV loading dose over 10–60 minutes (though heart failure guidelines do not recommend a bolus), followed by 0.125 to 0.75 mcg/kg/minute continuous infusion. Renal Adjustments: Elimination is primarily renal (83% excreted unchanged in urine, half-life of 2.4 hours). For CrCl ≤ 50 mL/min, the adult continuous infusion rate must be adjusted down sequentially from 0.43 mcg/kg/min (CrCl 41–50) down to 0.2 mcg/kg/min (CrCl ≤ 5). Pediatric rates also require reductions for CrCl < 50 mL/min. Administration Safety: Standard infusion is 200 mcg/mL, diluted in 0.45% or 0.9% NaCl or 5% Dextrose, run via a controlled device. It is not FDA-approved for intraosseous use, but the same doses can be given IO if IV access is unavailable. Critical Safety & Adverse Reactions Incompatibilities: Milrinone must never be co-administered with furosemide, as precipitation occurs immediately in the same line. It also cannot be given simultaneously with blood. Arrhythmias & Monitoring: Continuous ECG monitoring is mandatory. Milrinone carries a substantial risk of serious ventricular arrhythmias (VT up to 12%, VF 0.2%), atrial flutter/fibrillation (up to 8%), supraventricular tachycardia, and premature ventricular contractions. Hypotension & Other Risks: Hypotension occurs in 2.9% to 10.7% of patients. To reduce this risk, clinicians often avoid the loading dose in septic shock and neonatal PPHN. Thrombocytopenia is a delayed reaction occurring in up to 58% of patients.

CC Pharm | Dobutamine

Dobutamine is a direct-acting parenteral sympathomimetic inotrope. It primarily acts as an agonist at beta1-adrenergic receptors (with minor beta2 and alpha1 stimulatory effects) to increase myocardial contractility, stroke volume, and cardiac output. Unlike dopamine, it does not stimulate dopaminergic receptors or release norepinephrine. It has comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects, and minimally affects pulmonary vascular resistance. Primary Indications & Clinical Dosing: Low Output States: Used for short-term treatment of cardiac decompensation due to depressed contractility from organic heart disease, cardiac surgery, congestive heart failure, cardiogenic shock, or septic shock. Continuous IV Dosage: Initiate adults, children, and neonates at 0.5 to 1 mcg/kg/min, titrating to a usual dose of 2 to 20 mcg/kg/min based on response. Rates >20 mcg/kg/min may cause tachycardia or ectopy; 40 mcg/kg/min is rarely required. Diagnostics: Used in dobutamine stress echocardiography starting at 5 mcg/kg/min, titrating up to 40 mcg/kg/min. Special Populations: No dose adjustments are needed for renal or hepatic impairment. Critical Administration Rules: Dilution & Infusion: Must be diluted before use (maximum concentration 5,000 mcg/mL; standard adult concentration is 4,000 mcg/mL). Infuse using a controlled device, preferably into a large vein. Incompatibilities: Incompatible with sodium bicarbonate or strong alkaline solutions. Do not infuse dextrose-containing dobutamine through the same line as blood due to risk of pseudoagglutination/hemolysis. Physical Stability: Premixed bags in 5% Dextrose may turn pink over time due to slight oxidation, which does not impact potency. Intraosseous (IO): Not FDA-approved, but the same dose can be given via IO route during CPR if IV access is unfeasible. Pharmacokinetics & Safety Profile: Rapid Action: Infused intravenously, it has an onset of 2 minutes and a half-life of ~2 minutes. Severe Adverse Reactions: Can cause ventricular tachycardia, arrhythmia exacerbation, pulmonary edema, skin necrosis, and anaphylactoid reactions. Moderate Reactions: Includes hypertension, angina, palpitations, dyspnea, and premature ventricular contractions. Dosage titration must be guided closely by systemic blood pressure, heart rate, urine flow, and ectopic activity.

CC Pharm | Nitroprusside

Sodium nitroprusside is an ultra-potent, direct-acting peripheral vasodilator characterized by rapid hemodynamic action and highly toxic metabolites. This 80/20 summary distills its essential clinical, pharmacological, and nursing guidelines: 1. Mechanism & Hemodynamic Effects Mechanism: Direct action on arterial and venous smooth muscle; myocardial contractility is unaffected. Hypertension: Reduces afterload and causes venous pooling, decreasing arteriolar resistance. Heart Failure: Improves left ventricular performance, increasing cardiac index, cardiac output, and stroke volume while slowing heart rate. 2. Dosing & Clinical Administration Onset & Duration: Rapid onset (1-2 mins); effects persist for 1-10 mins after discontinuation. Titration: Confirm drug effect for 5 minutes before titrating to a higher dose. Dosing (Adults):Hypertensive Emergency: Start 0.3-0.5 mcg/kg/min; titrate by 0.5 mcg/kg/min every 5 mins. Max: 10 mcg/kg/min for 10 mins. Acute Heart Failure: Start 0.1-0.3 mcg/kg/min. Max: 10 mcg/kg/min (doses >400 mcg/min have no added benefit). Mitral Regurgitation: Start 15 mcg/min, titrate every 2 mins to reduce mean arterial pressure by 10-20 mmHg. Preparation & Administration:Dilute 50 mg in 250–1000 mL of 5% Dextrose (D5W). Never give direct IV injection. Solution is clear, colorless to red/brown; discard if blue, green, or bright red. Protect from light during administration with an opaque sleeve. Do not run other drugs in the same solution. 3. Boxed Warning: Cyanide & Thiocyanate Toxicity Cyanide Toxicity: Metabolism produces dose-related cyanide.Doses >2 mcg/kg/min exceed normal clearance. Buffering is exceeded in <1 hour at the max 10 mcg/kg/min rate. Action: Discontinue and consider sodium nitrite and sodium thiosulfate. Thiocyanate Toxicity: Cyanide converts to thiocyanate via mitochondrial rhodanase (renal half-life: 3 days).Life-threatening at 200 mg/L. Monitor plasma levels if cumulative doses exceed 7 mg/kg/day. Organ Impairment Risk:Hepatic disease: High susceptibility to cyanide toxicity. Renal Impairment: eGFR <30: limit mean infusion to <3 mcg/kg/min (Anuria: limit to 1 mcg/kg/min). 4. Nursing Interventions Monitoring: Mandatory continuous blood pressure monitoring, preferably via an intraarterial pressure sensor. Monitor urine output in heart failure. Safety: Use a volumetric infusion pump. Watch for hypotension, methemoglobinemia, bradycardia, or metabolic acidosis.

CC Pharm | Midazolam POSSIBLE [RSI]

Midazolam (Versed) 80/20 Clinical Summary Classes: Benzodiazepine sedative/hypnotic, anesthetic, anxiolytic, anticonvulsant. Mechanism: Enhances GABA-A receptors, increasing GABA affinity and opening chloride channels. This hyperpolarizes cell membranes, preventing excitation. Has twice the receptor affinity of diazepam. Pharmacokinetics: Metabolized by CYP3A4 to active, equipotent alpha-hydroxymidazolam. 97% protein-bound. Excreted via urine.IV: Onset 1.5–5m, duration 30–45m. Tissue accumulation in long infusions delays awakening. IM: Onset 5m, peak 15–30m. PO: Onset 10–30m, duration 40–70m, ~36% bioavailability. Intranasal (Nayzilam): Bioavailability 44–55%. Nasal burning lasts ~30s. Buccal/Rectal (Off-label): Onset is 10–30m; duration 40–90m. Black Box Warning & Complications Boxed Warnings: Requires specialized care setting, experienced clinician, and continuous cardio-respiratory monitoring. Profound risk of respiratory depression, apnea, arrest, and hypoxic encephalopathy/death. Coadministration with opioids or other CNS depressants severely increases risks of profound sedation, respiratory depression, coma, or death. Adverse Effects: Respiratory depression (8–23.3%), apnea (2.8–15.4%), severe hypotension, laryngospasm, bronchospasm, bradycardia, cardiac arrest. 80/20 Clinical & Nursing Pearls Monitoring: Continuously monitor respiratory effort and oxygenation (pulse oximetry) to detect hypoventilation or apnea early. Slow IV Push: Administer over ≥2 minutes; wait ≥2 minutes to assess effects before redosing. Avoid rapid push in neonates (risk of severe hypotension, hypoventilation, seizures). Antidote: Flumazenil must be immediately available to reverse respiratory depression. Note: Flumazenil can precipitate life-threatening seizures in chronic benzodiazepine users. Gradual Taper: Do not abruptly stop after continuous use (>1–2 weeks); taper gradually to avoid acute withdrawal (seizures, status epilepticus). Pediatric & Neonatal Safety: Preterm neonates have significantly slower clearance. Standard infusions are not recommended for preterm neonates <32 weeks due to adverse neurological risks. Avoid benzyl alcohol-containing injectables in neonates to prevent fatal "gasping syndrome". Renal/Hepatic: Half-life is prolonged in renal impairment; pediatric doses must be reduced by 25% (GFR 10–29) or 50% (GFR <10). Reduced clearance occurs in hepatic impairment. Why Choose This Drug? Preferred for rapid-onset, short-duration procedural sedation, amnesia, and acute seizure control (drug of choice for emergent IM seizure therapy)

CC Pharm | Diltiazem

Diltiazem (Cardizem) Clinical Summary 1. Action & Class: Benzothiazepine Class IV anti-arrhythmic/anti-anginal. Inhibits calcium influx across myocardial and vascular smooth muscle membranes. This slows AV conduction (prolonging the PR interval), decreases heart rate, and dilates coronary and systemic arteries, reducing afterload and blood pressure. It has fewer negative inotropic effects than verapamil. 2. Therapeutic Uses: Hypertension, stable/variant (Prinzmetal's) angina, and ventricular rate control in atrial fibrillation (AFib), atrial flutter, or PSVT. 3. Administration & Dosages: IV Push: Undiluted, over 2 minutes (0.25 mg/kg bolus; can repeat at 0.35 mg/kg in 15 minutes if needed). Continuous IV: 1 mg/mL dilution, starting at 10 mg/hour; titrate to a maximum of 15 mg/hour (duration >24 hours is not recommended). Oral: IR tablets (30–90 mg, 3–4 times daily). ER formulations (12- or 24-hour) range 120–360 mg/day (maximum 360–540 mg/day depending on formulation). Do not crush or chew ER formulations. 4. Complications & Adverse Effects: Severe: Bradycardia, high-degree AV block, asystole, heart failure, and life-threatening dermatologic reactions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Common: Peripheral edema (up to 15%), hypotension (4.3%), constipation (3.6%), headache (8.9%), and dizziness (10%). 5. Contraindications & Interactions: Contraindications: Severe heart failure, sick sinus syndrome, 2nd/3rd-degree AV block (without a functioning pacemaker), cardiogenic shock risk, or atrial arrhythmias presenting with pre-excitation (e.g., Wolff-Parkinson-White). Interactions: CYP3A4 substrate and inhibitor; can significantly raise levels of co-administered CYP3A4 substrates. Avoid/limit grapefruit juice (increases drug half-life). Concurrent beta-blockers severely compound the risk of AV block. 6. Nursing Interventions: Monitoring: Monitor ECG (PR interval) and blood pressure/heart rate continuously during IV therapy. Hold Parameters: Hold the dose and immediately notify the provider for severe bradycardia, new-onset heart block, or profound hypotension. Organ Function: Reduce dosage in hepatic impairment (increases half-life and bioavailability); no renal adjustments are required. 7. Client Education: Never split, crush, or chew ER formulations. However, Tiazac capsules can be opened and sprinkled on cool, non-hot applesauce. Change positions slowly to prevent orthostatic hypotension and syncope. Report severe rashes, swelling in lower extremities, or extreme fatigue immediately.

CC Pharm | Ketamine POSSIBLE [RSI]

Expected Action & Physiology Ketamine is a nonbarbiturate phencyclidine derivative that acts as an NMDA receptor antagonist, blocking glutamate to selectively interrupt thalamoneocortical pathways while stimulating the limbic system. This induces "dissociative anesthesia" where the patient is unresponsive to pain, but eyes remain open with intact corneal, light, and airway reflexes. It stimulates the sympathetic system, causing bronchodilation (ideal for asthma/bronchospasm), tachycardia, and hypertension. Direct negative inotropic effects can predominate in critically ill or catecholamine-depleted patients, causing hypotension. Cholinergic activation causes hypersalivation and elevated ICP/IOP. Therapeutic Uses & Dosing Uses: Anesthesia induction/maintenance, procedural sedation, RSI (preferred in shock/bronchospasm), plus off-label status asthmaticus, pain, and delirium/agitation. IV: Onset: 30–60s (rapid brain circulation); duration: 5–10 min. Dilute 100 mg/mL push and infuse slowly over ≥60s (max 0.5 mg/kg/min) to prevent respiratory depression. IM: Onset: 3–5 min; duration: 12–30 min. No dilution. Other: Intranasal (bioavailability 35–50%, onset 5–20 min). Oral/Rectal are less predictable due to high first-pass metabolism. Pharmacokinetics & Metabolism Highly lipid-soluble with low protein binding (12%), it rapidly distributes to the brain. It is metabolized by CYP3A4 into norketamine (active metabolite, one-third potency of ketamine). Half-life is 2–3 hours. Chronic use induces hepatic enzymes. No renal/hepatic dose adjustments are required. Complications & Nursing Pearls Emergence Reactions: Hallucinations, delirium, or nightmares occur in ~12% of patients. Intervention: Minimize verbal, tactile, and visual stimulation during recovery. Severe reactions can be terminated with benzodiazepines or barbiturates. Tonic-Clonic Movements: Purposeless movements can occur but do not indicate a light plane or need for more ketamine. Severe Risks: Laryngospasm, apnea, cardiac arrest, and increased ICP/IOP. Contraindication: Do not use as sole agent for procedures involving the larynx/pharynx or requiring muscle relaxation. Administration: Give on empty stomach to prevent vomiting/aspiration. Give an anticholinergic beforehand to limit oral secretions. Synergy ("Ketofol"): Combining ketamine and propofol reduces doses and improves safety. Propofol counteracts ketamine's nausea/emergence delirium; ketamine offsets propofol's hypotension/respiratory depression.

CC Pharm [RSI] | Rocuronium

The 80%: Core Clinical Guidelines & Actionable Insights Role: Intermediate-acting, nondepolarizing neuromuscular blocker (NMBA) for routine/RSI intubation, surgery, or mechanical ventilation. Mechanism: Competes with acetylcholine at motor end-plates. Paralysis moves from fine muscles (face/neck) to limbs, chest, abdomen, and diaphragm; recovery is in reverse. A vecuronium analog with 10–15% potency, it was developed to match succinylcholine's onset. Minimal histamine release/ganglion blockade makes bronchospasm, hypotension, or heart rate shifts rare. Crucial Administration:Rules: Give only after unconsciousness is induced with sedation, analgesia, and amnesia. Ventilatory support is mandatory. Do not mix with alkaline solutions (e.g., thiopental) due to acidic pH. Monitoring/Route: Direct IV over 5–10s; monitor with nerve stimulators (target 1–2 twitches). Infusions dilute up to 5 mg/mL (or 10 mg/mL undiluted). IM use is non-FDA-approved and discouraged (slow/inconsistent). Dosing Guidelines:Routine: Adults: 0.45–1.2 mg/kg (onset <2m); Pediatrics: 0.45–0.6 mg/kg (onset 60–75s); Neonates: 0.45–0.6 mg/kg (onset 1–2m). RSI: Adults: 0.6–1.2 mg/kg (onset <2m); Pediatrics: 0.6–1.2 mg/kg (usual: 1 mg/kg, onset 1–2 minutes); Neonates: 0.45–1.2 mg/kg. ICU Vent: Adults: 0.6–1 mg/kg bolus, then 0.1–1 mg/kg prn or 8–12 mcg/kg/min; Pediatrics/Neonates: 0.6 mg/kg bolus, then 5–10 mcg/kg/min. Surgery: Infusions: 10–12 mcg/kg/min (adults); 7–12 mcg/kg/min (pediatrics). The 20%: Pharmacokinetics, Special Populations, & Risks Pharmacokinetics: Extracellular distribution (not fat), ~30% protein bound. Tissue redistribution accounts for 80% of initial dose; maintenance infusion falls to ~20% of initial rate in 4–8 hours as tissues fill. CYP3A4 metabolizes it to an active form with 1/20th potency. Half-life: neonates (1.1h), older children (0.7–0.8h), adults (1.4–2.4h). Bolus duration: 22–67 min. Special Populations:Hepatic: Hepatic dysfunction prolongs recovery; ascites may require larger initial doses. Renal: Renal failure causes highly variable duration. Lactation: Poor lipid solubility and oral absorption make infant exposure unlikely (breastfeeding can resume 90m–5h post-anesthesia). Adverse & Storage: Severe risks: bronchospasm, anaphylaxis, angioedema, malignant hyperthermia, acute myopathy, thrombosis. Shortage update: FDA allows emergency extended vial use up to 2h at room temp or 4h refrigerated.

CC Pharm [RSI] | Etomidate

Etomidate (Amidate) is a short-acting sedative-hypnotic intravenous general anesthetic. Applying the 80/20 rule, this summary focuses on the core 20% of clinical details that deliver 80% of the practical knowledge needed for its safe administration: 1. Clinical Pharmacology & Mechanism Mechanism: Facilitates GABAminergic neurotransmission by increasing available GABA receptors, possibly by displacing endogenous inhibitors of GABA binding. Cerebral Effects: Reduces cerebral blood flow by 20% to 30%, lowers intracranial pressure (ICP) moderately for several minutes, and decreases intraocular pressure. Adrenal Impact: Inhibits steroidogenesis by blocking 11-beta-hydroxylation in the adrenal cortex, reducing plasma cortisol and aldosterone. This prevents its long-term use for ICU sedation. Pharmacokinetics: Onset of action is 0.5 to 1 minute, with a hypnotic duration of 3 to 5 minutes at a standard 0.3 mg/kg dose. It is 76% protein-bound, rapidly metabolized in the liver via ester hydrolysis, and has a 75-minute half-life. 2. Primary Indications & Dosing Anesthesia Induction: 0.2 to 0.6 mg/kg IV over 30 to 60 seconds (usual dose: 0.3 mg/kg). Subpotent Anesthetic Supplementation: 0.2 to 0.6 mg/kg IV over 30 to 60 seconds (usually lower than induction doses). Rapid-Sequence Intubation (RSI): 0.15 mg/kg IV for unstable patients and 0.3 mg/kg IV for stable patients. It is highly useful in head trauma, multiple traumas, cardiovascular disease, and non-sepsis hypotension as it lowers ICP with minimal systemic blood pressure impact. Procedural Sedation: 0.1 to 0.3 mg/kg IV (max: 20 mg/dose) over 30 to 60 seconds. Note: Etomidate does not have analgesic properties. Severe Hypercortisolism (Cushing's Syndrome): 0.04 to 0.1 mg/kg/hour IV infusion for ICU patients, or 0.025 mg/kg/hour for non-ICU patients. 3. Safety, Risks & Administration Administration: IV use only by trained personnel. Do not use for prolonged infusion. Adverse Reactions: Most common are myoclonia (74% incidence) and injection site reactions (1.2% to 42%). Severe reactions include apnea, laryngospasm, bradycardia, arrhythmia exacerbation, and anaphylactoid reactions. Adrenocortical insufficiency and hypoaldosteronism are potential delayed risks. Special Populations:Renal/Hepatic Impairment: Lower doses may be needed, particularly with cirrhosis. Lactation: Caution is advised. In post-Cesarean mothers, etomidate is excreted in colostrum but is undetectable by 4 hours; nursing is safe once the mother is awake and alert.

24 of 34